Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 8/20 | 0.52 |
| ▸ | PPARG | P37231 | 5/20 | 0.52 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.38 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6813922 | 0.93 | PPARA (0.53) | PPARAPPARGPPARDLMNAFFAR1 | |
| SCHEMBL6813832 | 0.87 | PPARA (0.48) | PPARAPPARGPPARDLMNAFFAR1 | |
| SCHEMBL6814654 | 0.86 | PPARA (0.71) | PPARAPPARGPPARDLMNAFFAR1 | |
| SCHEMBL4026049 | 0.85 | PPARG (0.50) | PPARAPPARGPPARDLMNAMEN1 | |
| SCHEMBL6817914 | 0.80 | FFAR1 (0.47) | PPARAPPARGPPARDFFAR1 | |
| SCHEMBL6813690 | 0.79 | PPARA (0.53) | PPARAPPARG | |
| SCHEMBL6813874 | 0.79 | PPARA (0.53) | PPARAPPARG | |
| SCHEMBL6817531 | 0.79 | PPARA (0.53) | PPARAPPARG | |
| SCHEMBL6813813 | 0.78 | PPARA (0.76) | PPARAPPARGPPARD | |
| SCHEMBL6817654 | 0.77 | PPARA (0.61) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237857-B1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | ASTRAZENECA AB (SE) | 2004-06-30 | — | — | EP | disclosed |
| US-6630509-B2 | Pharmaceutical medication associated with insulin resistance; patient with prophylaxis conditions having reduced sensitivity to insulin | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | disclosed |
| US-20030018207-A1 | Phenalkyloxy-phenyl derivatives | ASTRAZENECA AB (SE) | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018207-A1 | Phenalkyloxy-phenyl derivatives | GPR119, INSR, IAPP | PPARA 74/4885PPARG 47/4885PPARD 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.